TMCI Company Profile and Key Details

Treace Medical Concepts, Inc. (NASDAQ:TMCI) closed at $1.35 USD, losing -$0.11 (-7.53%) from the previous close of $1.46. The stock is currently within 5% of its 52-week low $1.31 and $8.87. With a market capitalization of about $87.20 million, Treace Medical Concepts, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.77). Key stats such as the average daily volume over the past year has been around 833.64 thousand shares, volume is running light vs its 52-week average. Headquartered in Ponte Vedra, FL, Treace Medical Concepts, Inc. operates in the Healthcare sector and the Medical - Devices industry. Led by CEO John T. Treace, the company employs approximately 477 people and listed since April 23, 2021. Treace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of medical devices for foot and ankle surgeons in the United States.

Short-term trend indicators are bullishly aligned (SMA20 2.24%, SMA50 -12.13%, SMA200 -57.59%). The stock’s 14-day RSI is 46.07 (neutral), while the ATR of 0.15 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -79.06% below its high and over 16.02% above its low. Average 10-day trading volume of 946.58 thousand shares is slightly above the 3-month average of 805.22 thousand, indicating heightened recent market interest.

Treace Medical Concepts, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$1.53. This means the shares are trading below this model’s fair value.

Treace Medical Concepts, Inc. generated EPS of -$0.79 over the past year. Five-year average earnings growth is -56.4%. Wall Street analysts project EPS growth of 3.03% annually over the next five years. The latest quarter delivered EPS of -$0.26. The next quarter is forecast at -$0.15. Next year's EPS is expected at $21.14. Analyst sentiment is neutral. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 9 Hold ratings, 0 Sell rating and 1 Strong Sell ratings. Price targets range from $8.60 to $4.00. The high target offers 537.04% upside. The low target suggests 196.3% downside. The mean target is $6.13. This offers 354.07% upside. Treace Medical Concepts, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended November 06, 2025, missed forecasts by -7.14%. The prior quarter beat by -3.45%. Over the last six quarters, Apple has recorded several small beats. These include 17.79% in August 06, 2024.

Treace Medical Concepts, Inc. has 63.17 million shares outstanding. The public float is 47.24 million shares, elevated short interest at 6.64% of float. This equals 3.18 million shares. The short ratio is 8.01 days. Institutional investors hold 82.0% of the float. Insiders own 25.36%. Treace John T. holds 6.80 million shares, TREACE JAMES T has 1.22 million shares and TIMBIE THOMAS E has 1.15 million shares.